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Abstract
Background: Little scientific evidence supports the efficacy of herbal medicines in the treatment of
degenerative arthritis of the knee. The purpose of this study is to evaluate both the efficacy and safety of
a finished Chinese herbal preparation Duhuo Jisheng Tang (DJT) in reducing symptoms of degenerative
osteoarthritis of the knee.
Methods: A prospective follow-up study was carried out in two hospitals in Taipei between April and
October 2005. Sixty-eight osteoarthritis patients, with symptoms diagnosed by radiologists, received DJT
at a rate of 2.5 g, twice daily for four weeks. Baseline scores were measured on the Western Ontario and
McMaster Universities Osteoarthritis (WOMAC) index, followed by further measures at the end of weeks
1, 2 and 4. The World Health Organization Quality of Life (WHOQOL) assessment was undertaken as a
secondary outcome, with pattern identification questionnaires being adopted. Regression models were
constructed to explore the score differences between the baseline and at weeks 2 and 4 by various
determinants including age, gender, body mass index (BMI), severity at baseline, use of rescue medication,
aversion to cold and flaccidity of the lower back and knees.
Results: Among the 68 participants, there were statistically significant reductions in the WOMAC index
scores for pain, stiffness and physical functioning in the second and fourth weeks, with effects first
appearing during week 2. By week 4, the mean WOMAC index scores had fallen from 22.2 (± 19.2) to
16.1 (± 16.2) for pain, from 28.1 (± 24.9) to 18.5 (± 20.3) for stiffness, and from 22.6 (± 18.0) to 18.2 (±
17.8) for physical functioning, while the global score for pain under the visual analogue scale (VAS) was
reduced from 38.7 (± 21.5) to 27.8 (± 19.8).
Conclusion: In the treatment of degenerative osteoarthritis of the knee, a 4-week therapy with the
Chinese herbal preparation DJT reduced pain and stiffness and improved physical functioning, but it was
less effective in treating flaccidity and aversion to cold.
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Background
Osteoarthritis (OA) is the most common form of joint
disease, with the most common location being the knee
[1]. As the patient ages, or the illness worsens, OA
becomes associated with incapacity and deterioration in
the quality of life owing to increased pain and loss of
mobility [2]. For those OA patients who are not suited for
surgery and/or those with ineffective medical treatment
and/or intolerable side effects [3], complementary and
alternative management approaches are frequently con-
sidered.
According to traditional Chinese medicine, arthritis
belongs to the category of bi-syndrome, which is attrib-
uted to the weakening of the body's protective energy
(weiqi). Weakened qi allows the incursion of the external
pathogens (waixie) such as 'Wind', 'Cold' and 'Dampness'
in Chinese medicine terminology. This incursion impedes
the normal flow of qi and results in pain and abnormal
function of the human body. A combination of symptoms
such as pain, stiffness, flaccidity and aversion to cold of
the knee signifies disharmony caused by 'Wind', 'Cold'
and 'Dampness'.
First documented about thirteen centuries ago in Qianjin
Yaofang (Invaluable Prescriptions for Ready Reference), an
ancient Chinese medicinal text [4,5], Duhuo Jisheng Tang
(DJT)  was used to treat symptoms caused by 'Wind',
'Cold' and 'Dampness'. DJT is a mixture of fifteen plant
species as follows: Radix Angelicae Sinensis (Danggui),
Radix Paeoniae Alba(Baishao), Radix et Rhizoma Glycyrrhizae
(Gancao), Radix Rehmanniae (Dihuang), Radix et Rhizoma
Ginseng (Renshen), Poria (Fuling), Radix Angelicae Pubes-
centis (Duhuo), Herba Taxilli (Sangjisheng), Radix Gentianae
Macrophyllae (Qinjiao),  Radix Saposhnikoviae (Fangfeng),
Radix et Rhizoma Asari (Xixin),  Rhizoma Chuanxiong
(Chuanxiong), Cortex Cinnamomi (Rougui), Cortex Eucom-
miae (Duzhong), Radix Cyathulae (Chuanniuxi) [5] (Table
1).
Aristolochic acid I (AA-I), a known nephrotoxin [6], is
found in a commonly used Chinese medicinal herb Xixin
which is originated from nine Asarum species (Aristolochi-
aceae). All products containing Xixin have been prohibited
in the US and Canada [7,8]. However, Xixin  remains
widely used in the DJT formula in Korea, Japan, Mainland
China and Taiwan. A previous study showed that the side
effects of DJT appeared at a daily dose of 9.0 g [11]. The
commonly administered dosage in Taiwan is 5 g per day
[9]. In 2003, the Committee of Chinese Medicine and
Pharmacy (CCMP) in Taiwan removed all Aristolochic
acid containing herbs except Xixin  from the approved
herbal products because of safety concerns. The commit-
tee also stipulated that the AA-I level in all Xixin prepara-
tions should be undetectable [10]. The current study is
intended to evaluate the efficacy of DJT on patients with
OA of the knee at a daily dose of 5.0 g. The observation
period was to last four weeks to test whether there are any
cumulative effects. We also intended to verify an ancient
indication that DJT was effective in treating pain, stiffness,
flaccidity of the lower back and knee and aversion to cold.
Methods
The herbal preparation DJT used in this study was pre-
pared under GMP (Good Manufacturing Practices) and
provided by Sun Ten Pharmaceutical (Taiwan). The
project was entirely funded by the CCMP to detect poten-
tial toxicity or adverse effects of DJT. Apart from providing
the batch of DJT, Sun Ten Pharmaceutical was not
involved in any other sponsorship, study design or moni-
toring of the participants.
Preparation of the herbs
All herbal components of DJT were prepared in a large
computer-controlled boiler where volatile oils of thera-
peutic values were collected and sprayed into a two-story
high vacuum drying chamber. The active ingredients of
the herbs were transformed into granulated compounds
five times more concentrated than the raw herbs. These
granulated compounds were then vacuum dried at low
temperatures before being siphoned into a separate ster-
ile-room where they were bottled, labeled and sealed. For
quality assurance of the active ingredients in DJT, HPLC
(high performance liquid chromatography) fingerprint-
ing was employed to identify substances in the final prod-
uct [12]. An extraction process required by the CCMP
regulations was performed, involving the use of water to
eliminate AA-I from Asarum heteropoides roots, a nephro-
toxic substance contained mostly in the leaves and/or aer-
ial parts of plants [13]. Liquid chromatography – tandem
mass spectrometry (LC/MS/MS) [14], a more sensitive
method, had been carried out by the Bureau of Food and
Drug Analysis of the Department of Health prior current
study to ensure that AA-I was at an undetectable level.
Each batch of DJT was also tested for E. coli, Salmonella
(bacteria count) and heavy metals.
Recruitment of subjects
This prospective follow-up study was coordinated from
the National Taiwan University, while participants were
enrolled through two research clinics in northern Taiwan:
Chinese Medicine Branch and Yangming Branch of the
Taipei City Hospital. Approval of the study was obtained
from the Joint Institutional Review Board for Traditional
Chinese Medicine of Taiwan (JIRBTCM94-0426-01). All
participants provided signed and informed consents
before taking part in the study.Chinese Medicine 2007, 2:4 http://www.cmjournal.org/content/2/1/4
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Inclusion criteria
Participants were recruited through newspaper advertise-
ments and flyers posted in clinics and health fairs between
April and October 2005. The status of osteoarthritis of the
knee was confirmed by radiography (mild to moderate
osteophytes and/or joint space narrowing). Qualified par-
ticipants were at least 18 years of age with symptomatic
osteoarthritis in at least one knee and had sought medical
help over the two-week period prior to the study. Partici-
pants had not been involved in any other medical trials
three months prior to the study. Participants were
required to discontinue the use of any current medica-
tions, including any conventional or herbal products for
arthritis, at least two weeks prior to the initial screening
for the study.
Exclusion criteria
Rheumatoid, inflammatory or any other type of arthritis;
arthroscopy or intra-articular corticosteroids/hyaluronic
acid injections in the previous month; any evidence of
renal or liver dysfunction as defined by a level of at least
1.5 times the upper reference limit [serum creatinine: 1.3
mg/dl, blood urea nitrogen (BUN): 22 mg/dl, serum
aspartate-aminotransferase (AST): 25 IU/L, alanine-ami-
notransferase (ALT): 29 IU/L]; uncontrolled hyperten-
sion; diabetes mellitus; or any signs of cancer.
Study design and procedure
All nurses involved in the study attended a standardized
training session to ensure consistency and to meet GCP
(Good Clinical Practices) requirements in the study pro-
tocol. Participant eligibility was assessed during the first
two visits to the clinic. Following the initial screening
visit, participants entered a run-in phase to determine
baseline data on their symptoms and their quality of life;
each participant also underwent a health assessment
including complete blood counts and biochemical func-
tion tests. These data were collected to ensure the eligibil-
ity criteria for each participant, and to screen out
respondents with potential poor compliance. Following
the run-in phase, each participant was provided with suf-
ficient DJT to begin treatment at a dose of 2.5 g twice
daily.
Subsequent study visits were scheduled for the first, sec-
ond and fourth weeks, with any symptoms of the knee
and adverse events being assessed at each visit. At the end
of the trial, the participants received a further physical
examination, including blood tests. Participants were con-
tacted by telephone one to two days prior to each visit in
order to encourage their continued compliance. Through-
out the study period, leftover package counts were under-
taken so as to monitor each participant's compliance. The
consumption of non-steroidal anti-inflammatory drugs
(NSAIDs) rescue medication was also recorded at each
visit.
Efficacy/Tolerability
The primary outcome parameters evaluated prior to and
during the four-week intervention were pain, stiffness and
physical functioning subscales, along with the global pain
assessment using a 100-mm 'visual analog scale' (VAS)
from the Western Ontario and McMaster Universities
Osteoarthritis (WOMAC) index [15]. We purchased the
WOMAC Chinese language form directly from the author
[16]. Changes in the quality of life were also assessed
using the World Health Organization Quality of Life ques-
tionnaire – Taiwan brief version (WHOQOL-BREF) [17].
Each subject's physical constitution was also categorized
using a questionnaire for pattern identification, or 'bian
Table 1: Nomenclature of Chinese herbs used in Duhuo Jisheng Tang
Pharmaceutical name Chinese pinyin Latin botanical name
Radix Angelicae Sinensis Danggui Angelica sinensis (Oliv.) Diels
Radix Paeoniae Alba Baishao Paeonia lactiflora Pall
Radix et Rhizoma Glycyrrhizae Gancao Glycyrrhiza uralensis Fisch.
Radix Rehmanniae Dihuang Rehmannia glutinosa Libosch.
Radix et Rhizoma Ginseng Renshen Panax ginseng C. A. Mey.
Poria Fuling Poria cocos (Schw.) Wolf
Radix Angelicae Pubescentis Duhuo Angelica pubescens Maxim.f. biserrata Shan et Yuan
Herba Taxilli Sangjisheng Taxillus chinensis (DC.) Danser
Radix Gentianae Macrophyllae Qinjiao Gentiana macrophylla Pall.
Radix Saposhnikoviae Fangfeng Saposhnikovia divaricata (Turcz.) Schischk.
Radix et Rhizoma Asari Xixin Asarum heterotropoides Fr. Schmidt var. mandshuricum (Maxim.) Kitag.
Rhizoma Chuanxiong Chuanxiong Ligusticum chuanxiong Hort.
Cortex Cinnamomi Rougui Cinnamomum cassia Presl
Cortex Eucommiae Duzhong Eucommia ulmoides Oliv.
Radix Cyathulae Chuanniuxi Cyathula officinalis KuanChinese Medicine 2007, 2:4 http://www.cmjournal.org/content/2/1/4
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zheng' in Chinese medical terminology, based on the cri-
teria recommended in Zhongyao Xinyao Linchuang Yanjiu
Zhidao Yuanze (The Guidelines for Clinical Research on New
Chinese Medicines) [18]. The questionnaire consisted of
categories as follows: frequency of pain, aversion to cold
and flaccidity of the lower back and knees (each of which
were assessed in terms of 'occasional or less', 'often', or 'so
frequent as to interfere with work'), and duration of stiff-
ness ('less than one hour' or 'more than one hour').
The WOMAC index is a multi-dimensional, disease spe-
cific, self-administered, health status measure. It probes
clinically important, patient-relevant symptoms in the
areas of pain, stiffness and physical function in patients
with knee osteoarthritis. The instrument comprises 24
questions (five on pain, two on stiffness and 17 on phys-
ical functioning) and can be completed in less than five
minutes. Weightings were introduced to add together the
five items on pain as a total sum score which predomi-
nantly quantifies the severity of knee pain in different
daily activities, with the same process being carried out on
stiffness and physical functioning [19]. The VAS version of
the WOMAC is valid, reliable and sufficiently sensitive for
the detection of clinically-important changes in health
status following a variety of interventions [20,21]. The
Taiwan version of the WHOQOL-BREF comprises four
domains (i.e. physical, psychological, social and environ-
mental) containing 24 facets, and two national items on
overall quality of life (QOL) and general health [17], with
higher scores indicating superior QOL.
Safety assessment
Routine hematology and biochemistry data were collected
at the baseline and at week 4, including complete blood
count and platelets, serum levels of creatinine, BUN, AST,
ALT, albumin/globulin (A/G), uric acid and urine levels of
N-acetyl-β-D-glucosaminidase and retinol binding pro-
tein. A research nurse also actively monitored any adverse
events and recorded any unexpected signs, symptoms or
feelings during the study period.
Statistical analysis
Our analysis focused mainly on changes in the three-
domain construct of the WOMAC assessment (pain, stiff-
ness and physical function) along with the WHOQOL
measures. The treatment effects were described as changes
of the mean differences among the participants between
the scores measured during each visit at weeks 1, 2, and 4
and at baseline. Separate linear regression models were
constructed for the response variables of the differentiated
scores on the pain, stiffness and physical functioning sub-
scales, the VAS-pain and the WHOQOL-BREF domains.
The explanatory variables in the final regression model
were gender, age, baseline severity of osteoarthritis, the
interaction between age and gender, the BMI (in kg/m2),
aversion to cold, flaccidity of the lower back and knees
and usage of NSAID rescue drugs. For us to examine the
improvement across the 3 visits, two indicator variables
for visits at weeks 2 and 4 were also included in the regres-
sion model. The coefficients of the two indicator variables
represent the differences between the average value of
measured scores for the visits at weeks 2 and 4 versus
those at week 1. The error terms were assumed to be cor-
related among the three repeated measurements on each
participant. Finally, each single WOMAC score item was
also examined separately so as to identify any WOMAC
items sensitive to treatment by DJT. The estimates of coef-
ficients and standard errors of the estimates in the multi-
ple regression models with correlated error terms were
obtained by using generalized least squares function of
the package nlme version 3.1–60 in a free statistical soft-
ware R version 2.1.1 [22].
Results
Subjects
Of the 87 sample patients, 18 were deemed ineligible. The
principal reasons for ineligibility were uninterested in par-
ticipation (n = 9), abnormal liver function (n = 5), abnor-
mal renal function (n = 2) and no evidence of
osteoarthritis (n = 2). Sixty-eight of the initial 69 partici-
pants completed the four-week study. The main reason for
the withdrawal was lack of efficacy during the first week of
treatment. The demographic and clinical characteristics of
the study subjects are summarized in Table 2. Among
them, 37% were male, 82% married and 59% having
attained senior high school education or above. Seven of
the 68 took less than 80% of the prescribed dosage over
the study period for the reason of lack of response to DJT.
Patients with poor compliance had significantly lower
scores in severity of pain and physical functioning and
had significantly higher scores in physical QOL than those
with good compliance.
Efficacy on pain, stiffness and physical functioning
After two weeks of treatment, there were significant and
persistent improvements in each of the WOMAC sub-
scales and also in the 10 cm VAS score for knee pain
(Table 3). The magnitudes of the improvements in the
WOMAC subscales were 27.5% for pain, 34.2% for stiff-
ness and 19% for physical functioning. There was also a
28.2% improvement in the VAS score.
After four weeks of treatment, 44 of the 68 patients
reported no change in the symptom of flaccidity; nine
reported improvements, whereas fifteen reported deterio-
ration. Thirty-eight patients reported no change in the
symptom of aversion to cold after four weeks of treat-
ment; fourteen reported improvements, while16 reported
deterioration.Chinese Medicine 2007, 2:4 http://www.cmjournal.org/content/2/1/4
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There were no significant improvements in these two
symptoms after the treatment.
The results of the multiple linear regression analyses indi-
cate the effects of the different determinants on the out-
come scores of the VAS for pain and different WOMAC
subscales (Table 4). After rescue medication and other
determinants had been controlled, the model construc-
tions demonstrated significant improvements in the
severity of pain, stiffness and physical functioning after
Table 2: Baseline demographic and clinical characteristics for the 68 participants
Definition Mean (SD)
Age (years) 59.2 (10.2)
Body mass index 24.0 (3.2)
Gender
% Male 37
Religion
% Buddhist 56
% Christian 10
Marital states
% Married 82
% Divorced/Widowed/Separated 15
Education
% Junior high or below 41
% University or above 34
Pain in visual analogue scale 38.7 (21.5)
WOMAC Scoresa
Pain 22.2 (19.2)
Stiffness 28.1 (24.9)
Physical functioning 22.6 (18.0)
Flaccidity of the lower back and knees
% Mild 54
% Moderate 32
% Severe 13
Aversion to cold
% Mild 73
% Moderate 12
% Severe 15
WHOQOL-BREF Scoresb
Physiological domain 12.9 (2.4)
Psychological domain 13.0 (2.2)
Social domain 13.5 (1.9)
Environment domain 13.5 (1.7)
a WOMAC refers to the Western Ontario and McMaster Universities Osteoarthritis Index.
b WHOQOL – BREF refers to the World Health Organization Quality of Life – brief version.
Table 3: Means and standard deviation of major variables measured at baseline and weeks 1, 2 and 4
Variable definition Baseline Week 1 Week 2 Week 4
WOMAC Scoresa Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Pain 22.2(19.2) 21.4(20.9) 16.9(16.9) ** 16.1(16.2) **
Stiffness 28.1(24.9) 25.8(23.1) 17.4(18.5) *** 18.5(20.3) ***
Physical functioning 22.6(18.0) 22.4(19.5) 18.2(15.8) ** 18.2(17.8) *
Pain in visual analogue scale 38.7(21.5) 33.0(20.7)* 27.0(21.5) *** 27.8(19.8) ***
WHOQOL-BREF Scoresb ----
Physiological domain 12.9(2.4) - - 13.2(1.9)
Psychological domain 12.4(2.0) - - 12.3(1.5)
Social domain 13.5(1.9) - - 13.6(2.2)
Environment domain 13.5(1.7) - - 13.4(1.5)
a WOMAC refers to the Western Ontario and McMaster Universities Osteoarthritis Index.
bWHOQOL – BREF refers to the World Health Organization Quality of Life – brief version.
* indicates P < 0.05; ** indicates P < 0.01; and *** indicates P < 0.001.Chinese Medicine 2007, 2:4 http://www.cmjournal.org/content/2/1/4
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week 2 (which also persisted through week 4), with sub-
stantial treatment effects on the stratum of the most severe
pain (baseline VAS score >4 cm, n = 32). The frequency of
either flaccidity or aversion to cold were not significantly
affected in any of the above major outcome scores, and
there were no consistent improvements with regard to
these two symptoms after week 4.
Safety Issue
There were no significant changes in all tested biomarkers
including the highly sensitive indicators of nephrotoxicity
[23,24] after the 4-week DJT  intervention. Only four
adverse drug reactions were potentially related to DJT
treatment, involving single events of skin discoloration,
flashes, diarrhea and tachycardia.
Discussion
This study is observational in nature and lacks a rand-
omized placebo group. We, therefore, cannot make strong
inference from the outcomes reported by the patients.
However, the present study recruited only the patients
with radiographically-verified OA of the knee and used
self-comparison to rule out the potential confounders of
the BMI, age, exercise and socioeconomic status [25]. This
study also showed that the supposed efficacy of DJT on
flaccidity of the lower back and knee and aversion to cold,
as indicated in Qianjin Yaofang (Invaluable Prescriptions for
Ready Reference) [4], were not reflected in the 'relief of
symptoms' or 'physical functioning' scores for OA of the
knee (Table 4).
In current practice of Chinese medicine, DJT is usually
prescribed as a treatment for a combination of symptoms
of pain, stiffness, flaccidity and/or aversion to cold. The
results of this study suggest that the 4-week treatment of
the DJT preparation may not be effective in treating flac-
cidity and/or aversion to cold. As most participants in this
study experienced only mild or moderate symptoms of
flaccidity and/or aversion to cold, very limited room may
have been left for improvements of the symptoms (Table
2).
Following the recommendations of the World Health
Organization, we used the WHOQOL-BREF, a multi-
dimensional measure of QOL, as our secondary outcome
in this study [26]. However, there were no statistically sig-
nificant changes in the scores of either the WHOQOL
domains or the different facets (Table 3) for those patients
suffering from pain or stiffness who showed significant
improvements. This may be due to the small sample size
and the generic nature of the WHOQOL-BREF which, for
most of the OA patients in this study with only mild
symptoms, may not be so responsive.
Since  DJT  contains  Xixin  which may contain AA-I, an
undetectable level of AA-I in the medications of the study
was assured in compliance with the regulations of the
CCMP. In contrast to the positive control sample directly
taken from Xixin, no AA-I was detected in the independent
chemical analysis of DJT by LC/MS/MS in this study.
The DJT dosage used in this study (2.5 g twice daily) is
smaller than that in a previous study which showed that
an oral daily dose of 9 g of DJT had a similar toxicity pro-
file to that of diclofenic [11]. The results of this study pro-
vide (about IIb level [26]) that the participants seemed
well tolerant of the 5.0 g daily dose of the DJT preparation
for four weeks, and that the four adverse drug reactions
noted earlier were not serious enough to have caused any
withdrawal by any of the participants.
Table 4: The estimates of regression coefficients and standard errors for modeling outcomes of VAS for pain and WOMAC subscales
WOMAC subscalesb
Variable definition VAS for paina
Pain Stiffness Physical function
Coeff. S.E. Coeff. S.E. Coeff. S.E. Coeff. S.E.
Severity at baseline -0.40*** 0.08 -0.42*** 0.07 -0.51*** 0.07 -0.34*** 0.07
Mean score improvement at week 2 vs. week 1 -6.16*** 1.84 -4.62** 1.55 -8.52*** 2.11 -4.24** 1.34
Mean score improvement at week 4 vs. week 1 -5.13*** 1.84 -5.28*** 1.55 -7.22*** 2.11 -4.04** 1.34
Age 0.00 0.24 0.21 0.20 0.33 0.23 0.39* 0.18
Gender (female vs. male) -15.74 19.73 3.83 16.67 2.18 19.38 13.26 15.06
Body Mass Index (<25 vs. >= 25) -0.68 3.44 -1.03 2.92 -1.25 3.44 -1.19 2.65
Rescue drug (used vs. not used) 6.03 3.38 4.27 2.85 3.79 3.65 4.86 2.52
Aversion to cold (mild vs. moderate or severe)c 3.86 3.94 7.59 3.31 8.12* 3.88 3.93 3.09
Flaccidity of lower back/knee (mild vs. moderate or severe) c 3.03 3.46 2.03 2.87 -1.36 3.34 0.65 2.63
aVAS = visual analogue scale as the dependent variables.
bRefers to the three subscales of the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Index as the dependent variables.
cPattern identification as the independent variables.
*indicates P < 0.05; ** indicates P < 0.01; and *** indicates P < 0.001.Chinese Medicine 2007, 2:4 http://www.cmjournal.org/content/2/1/4
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It should be noted that the results from the current study
may not represent those of other types of DJT prepara-
tions, as different manufacturing processes may affect the
biological activities and toxicity levels of herbs such as
Xixin. Moreover, as the participants in this study were only
Taiwanese patients suffering from OA of the knee during
late spring and early autumn, we should remain cautious
about generalizing these findings to cover patients in
other settings, or indeed, to different racial groups.
Conclusion
The participants indicated symptomatic improvements in
pain, stiffness and physical functioning as demonstrated
in the WOMAC subscale scores which began to decrease
after two weeks of treatment. Multiple regression analyses,
however, showed that the DJT preparation was less effec-
tive on flaccidity of the lower back and knees and aversion
to cold. The dosage form and prescription pattern of the
DJT preparation described in the current study may be
used as a complementary or alternative treatment of pain,
stiffness and other physical functioning problems in
patients with OA of the knee. As the results from the cur-
rent study could have been confounded by placebo effect,
natural fluctuation, insufficient follow-up time and/or
other unobserved factors, a prospective randomized, dou-
ble-blind, controlled trial to further evaluate the efficacy
of DJT on OA patients is warranted in future studies.
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